Product logins

Find logins to all Clarivate products below.


ENT Devices – Market Insights – Asia Pacific (Supplemental)

Driven by the increasing prevalence of ear, nose, and throat disease and patient awareness of ENT procedures in this region, the Asia Pacific ENT device market will continue to expand through 2033, despite the competition from nonsurgical alternative treatments, such as antibiotics. Moreover, there will be increasing adoption of innovative and premium-priced products, such as flexiblescopes, RF handpieces, and powered instruments; as a result, the Asia Pacific market for ENT devices will grow at a modest pace.

This Medtech 360 Report provides high-level market metrics for ENT devices in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the region from 2019 through 2033.

Table of contents


Related Medtech Insights Reports

Report
Structural Heart Closure Devices – Market Insights – Asia Pacific
The Asia Pacific structural heart closure device market will grow strongly overall through 2034, supported by rising AF prevalence, increasing physician confidence in structural heart interventions…
Report
Biosurgical Agents – Market Insights – US
The biosurgical agent market in the US will experience modest growth through 2034. This growth will be fueled by rising surgical procedure volumes that require biosurgical agent and strong…
Report
Biosurgical Agents – Market Insights – Europe
The Europe biosurgical agent market will exhibit modest growth over the forecast period. This expansion will be fueled by a continued preference for biosurgical agents over alternative solutions,…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…
Report
Biosurgical Agents – Market Insights – Latin America
The Latin American biosurgical agent market will grow modestly through 2034; although demand for biosurgical agents will rise—supported by favorable regional demographics, expanded indication…